Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

著者: Xavier Pivot, Joseph Gligorov, Volkmar Müller, Peter Barrett‐Lee, Sunil Verma, Ann Knoop, Giuseppe Curigliano, Semiglazov Vf, Guillermo López-Vivanco, Valerie Jenkins, Nana Scotto, Stuart Osborne, Lesley Fallowfield - The Lancet 2013 被引用: 226